<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:50</td>
<td>Welcome and introduction</td>
<td>Anna Sureda (SP) &amp; Nico Cagelman (DE)</td>
<td>Anna Sureda (ES)</td>
</tr>
<tr>
<td>09:00 – 09:20</td>
<td>ITCTC introduction and what is EBMT</td>
<td>Nico Cagelman (DE)</td>
<td></td>
</tr>
<tr>
<td>09:20 – 09:40</td>
<td>A brief overview of JACIE</td>
<td>Lynn Manson (UK)</td>
<td></td>
</tr>
<tr>
<td>09:40 – 09:50</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:50 – 11:30</td>
<td>Session 1: Preparing for transplant</td>
<td>Mohamad Mohty (FR) &amp; Carmelo Curnari (IT)</td>
<td>Neema Mayor (UK)</td>
</tr>
<tr>
<td>09:50 – 10:10</td>
<td>HLA system and impact on donor selection: what’s new?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10 – 10:30</td>
<td>Conditioning regimen: a practical guide</td>
<td>Mohamed Mohty (FR)</td>
<td></td>
</tr>
<tr>
<td>10:30 – 10:50</td>
<td>What a transplant physician should know about germ line predisposition traits for donor selection</td>
<td>Carmelo Curnari (IT)</td>
<td></td>
</tr>
<tr>
<td>10:50 – 11:10</td>
<td>Mobilization and collection / HSC cryopreservation and quality assessment</td>
<td>Oscar M. Pello (SP)</td>
<td></td>
</tr>
<tr>
<td>11:10 – 11:30</td>
<td>Discussion, Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>Session 2: Monitoring after transplant</td>
<td>Florent Malard (FR) &amp; Fabio Ciceri (IT)</td>
<td>Alexandros Spyridonidis (GR)</td>
</tr>
<tr>
<td>12:00 – 12:20</td>
<td>Measurable residual disease, chimerism assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20 – 12:40</td>
<td>Mechanisms of leukemia immune evasion and their role in post-transplant relapse</td>
<td>Cristina Toffalori (IT)</td>
<td></td>
</tr>
<tr>
<td>12:40 – 12:50</td>
<td>Case report: Adoptive immunotherapy with cytokine induced killer cells for Philadelphia-positive acute lymphoblastic leukemia relapsed after allogeneic stem cell transplantation and unresponsive to tyrosine kinase inhibitors. A case report</td>
<td>Federica Frenza (IT)</td>
<td></td>
</tr>
<tr>
<td>12:50 – 13:00</td>
<td>Discussion, Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 – 13:45</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45 – 14:30</td>
<td>Industry Symposium on “Post-transplant – How to treat GvHD with ECP in 2023”</td>
<td>Kindly sponsored by Therakos</td>
<td></td>
</tr>
<tr>
<td>14:30 – 16:00</td>
<td>Session 3: GvHD</td>
<td>Zinaida Peric (HR) &amp; Kristin Rathje (DE)</td>
<td>Florent Malard (FR)</td>
</tr>
<tr>
<td>14:30 – 14:50</td>
<td>Prophylaxis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50 – 15:10</td>
<td>Treatment Acute GvHD</td>
<td>Olaf Penack (DE)</td>
<td></td>
</tr>
<tr>
<td>15:10 – 15:30</td>
<td>Treatment Chronic GvHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 – 15:40</td>
<td>Case report: Polymyositis: A Rare Manifestation of Chronic GvHD</td>
<td>Ang Chieh Hwee (SG)</td>
<td></td>
</tr>
<tr>
<td>15:40 – 15:50</td>
<td>Case report: Peeling and laser therapy for management of face hyperpigmentation after chronic graft versus host disease: a case report</td>
<td>Lucas Vogt Cota (BR)</td>
<td></td>
</tr>
</tbody>
</table>
8th International Transplant and Cellular Therapy Course
Barcelona, Spain
8-10 September 2023

Preliminary Programme

15:50 - 16:00 Discussion. Q&A
16:00 - 16:30 Coffee Break

16:30 - 18:00 Session 4: Infections and other complications after transplant
Chairs: Rafael de la Cámara (SP) & Sheila Torrado (ES)
16:30 - 16:50 Craft failure and poor graft function
Annalisa Ruggeri (IT)
16:50 - 17:10 Respiratory virus
José Luis Piñana (SP)
17:10 - 17:30 CMV
17:30 - 17:40 Case report: Haploidentical transplant recipient with severe pneumonia by Respiratory Syncytial Virus (RSV): a case report.
Gloria Catalano (IT)
17:40 - 17:50 Case report: Cerebral Toxoplasmosis After Allogenic Stem Cell Transplant In A Patient Living With HIV
Tien Gen Wong (MY)
17:50 - 18:00 Discussion. Q&A

18:15 - 19:30 Welcome reception & poster walk

Saturday, 9 September 2023
Plenary room: Paranimf | Adults' Track

08:45 - 10:15 Session 5: Indications for HCT in Adults (I)
Chairs: Fabio Ciceri (IT) & Esra Gülder (TR)
08:45 - 09:15 Introductory Case + The role of HCT in AML
Eolia Brissot (FR)
09:15 - 09:45 Introductory Case + HCT in ALL: where do we stand?
Sebastian Giebel (PL)
09:45 - 09:55 Case report: Refractory acute myeloid leukemia with complex karyotype in young male
Piotr Piętowski (PL)
09:55 - 10:05 Case report: Rapid turnaround of germline WGS facilitating donor selection in AML with CEBPA mutation.
Sally Thomas (UK)
10:05 - 10:15 Discussion

10:15 - 10:45 Coffee Break

10:45 - 12:15 Session 6: Indications for HCT in Adults (II)
Chairs: Donal McLornan (IE) & Alex Rampotas (ES)
10:45 - 11:15 Introductory Case + HCT in MDS in the new molecular era of IPSS-M
Kristin Rathje (DE)
11:15 - 11:45 Introductory Case + HCT in MPD: a state of the art and considerations on its role as opposed to conservative strategies
Angela Hwang (UK)
Donal McLornan (IE)
11:45 - 11:55 Case report: Successful salvage of Myelofibrosis with Frank Relapse Post-Allogeneic Stem Cell Transplantation Using Adoptive Immunotherapy with DLI
Alex Rampotas (UK)
11:55 - 12:05 Case report: Haploidentical hematopoietic cell transplantation for blast phase myelofibrosis
Deepesh P. Lad (IN)
12:05 - 12:15 Discussion. Q&A
12:15 – 13:00  Lunch Break

13:00 – 13:30  Session 7: Indications for HCT in Adults (III)
   Chairs: Raffaella Greco (IT) & Rosamaria Nitti (IT)
   13:00 – 13:30  Introductory Case + HCT in PCD: who should we candidate?  Patrick Hayden (IE)
   13:30 – 14:00  Introductory Case + HCT in AID: an overview  Andrea Acerbis (IT)
                    Raffaella Greco (IT)

14:00 – 14:10  Case report: Multi-organ chronic graft-vs-host-disease mimicking MDA5 Autoantibody-Associated dermatomyositis  Niccolò Rampi (IT)

14:10 – 14:20  Case report: Allogeneic hematopoietic stem cells transplantation in adult patient with immunodeficiency caused by hemizygous mutation of the XIAP gene - a case report  Paweł Kiciński (PL)

14:20 – 14:30  Discussion, Q&A

14:30 – 15:00  Coffee Break

15:00 – 16:15  Session 8: Long-term survivorship after HCT (joint session)
   Chairs: Natacha Bolanos (IT) & Alexandra Martinez (ES)
   15:00 – 15:30  Late Complications: an overview of Endocrine and fertility complications  Annalisa Paviliani (ES)
   15:30 – 15:50  Post-transplant therapeutic strategies in acute leukemias  Arnon Nagler (IL)
   15:50 – 16:00  Case report: Simultaneous Presentation of VOD/SOS and PTLD: a Case Report of Two Uncommon Complications after Allogeneic Stem Cell Transplantation  Federica Frenza (IT)
   16:00 – 16:15  Discussion

16:15 – 16:45  Keynote Lecture
   Chair: Anna Sureda (ES)
   From Allo transplant to Gene therapy in SCD / Thalassemia  Selim Corbacioglu (DE)
Saturday, 9 September 2023
Aula 2 | Paediatrics’ track

08:45 - 10:15  Session 1: Acute Leukaemia in Children
  Chairs: Krzysztof Kalwak (PL) & Petr Sedlacek (CZ)
  08:45 - 09:05  HCT for ALL: why, when and how?  Petr Sedlacek (CZ)
  09:05 - 09:25  AML in Children  Robert Wynn (UK)
  09:25 - 09:45  Paediatric CAR-T Cell Therapy: where do we stand?  Krzysztof Kalwak (PL)
  09:45 - 09:55  Case presentation: Excellent outcome of children with PB-ALL relapsing post HSCT, who had very low disease burden at the time of LDC before CAR-T cell infusion  Karolina Magdalena Liszka (PL)
  09:55 - 10:15  Discussion, Q&A

10:15 – 10:45  Coffee Break

10:45 - 12:15  Session 2: Inborn Errors
  Chairs: Bénédicte Neven (FR) & Robert Wynn (UK)
  10:45 - 11:05  HCT and gene therapy of Metabolic Disease  Robert Wynn (UK)
  11:05 - 11:25  HCT for immunodeficiencies  Bénédicte Neven (FR)
  11:25 - 11:45  HCT for immune dysregulation  Bénédicte Neven (FR)
  11:45 - 11:55  Case presentation: Simultaneous haploidentical HSCT in 2 brothers with chronic granulomatous disease using PT-Cy – a case report  Pik Ki Chan (CH)
  11:55 - 12:15  Discussion, Q&A

12:15 – 13:00  Lunch Break

13:00 - 14:30  Session 3: Bone marrow failure, myelodysplastic syndromes, and selected complications
  Chairs: Carlo Dufour (IT) & Katharina Kleinschmidt (DE)
  13:00 - 13:20  Congenital bone marrow failure syndromes  Carlo Dufour (IT)
  13:20 - 13:40  MDS and JMML  Dominik Turkiewicz (SE)
  13:40 - 14:00  What is new in paediatric VOD in 2023?  Katharina Kleinschmidt (DE)
  14:00 - 14:10  Case presentation: Allogenic haematopoietic stem cell transplant (HSCT) in a child with somatic K-RAS Positive Juvenile Myelomonocytic Leukaemia (JMML) and challenging secondary haemo-phagocytic lymphohistocytosis (HLH)  Purushotham Ramachandran (UK)
  14:10 - 14:30  Discussion, Q&A
### Session 1: Preparation, cell collection, conditioning, and infusion

**Chairs:** To be announced

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Right donor, right patient, right time</td>
<td>Annika Kisch (SE)</td>
</tr>
<tr>
<td>09:05</td>
<td>Role of the apheresis nurse - more than just cell collection</td>
<td>Natalia Lorente del Rio (ES)</td>
</tr>
<tr>
<td>09:25</td>
<td>Conditioning regimens - different approaches and why</td>
<td>Marijke Quaghebeur (NL)</td>
</tr>
<tr>
<td>09:45</td>
<td>Cell infusion: stem cell, CART and lymphocyte infusions - exploring the differences</td>
<td>Julia Ruiz Pato (ES)</td>
</tr>
<tr>
<td>10:05</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 2: Post-infusion care

**Chairs:** To be announced

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45</td>
<td>Nutritional support - the current guidance</td>
<td>Elin Öfverberg (SE)</td>
</tr>
<tr>
<td>11:05</td>
<td>CVCs - evidencing best practice in 2023</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>Neutropenic fever and the sepsis 6</td>
<td>Sandra Schönfeld (CH)</td>
</tr>
<tr>
<td>11:45</td>
<td>Mucositis - prevention, assessment, and care</td>
<td>Ida Breemer (NL)</td>
</tr>
<tr>
<td>12:05</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 3: Supportive care

**Chairs:** To be announced

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Endocrine complications and hormone deficiencies</td>
<td></td>
</tr>
<tr>
<td>13:20</td>
<td>Fungal infections and treatment</td>
<td>Daniel Kisielewski (DE)</td>
</tr>
<tr>
<td>13:40</td>
<td>Haemorrhagic cystitis - the role of PTCy, other causes, care, and consequences</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Advanced care planning conversations and palliative care: where they fit</td>
<td>Hilda Mekelenkamp (NL)</td>
</tr>
<tr>
<td>14:20</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 4: Essential update

**Chairs:** To be announced

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>GVHD new therapies and old assessment</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Paediatric update</td>
<td>Thomas Jezequel (FR)</td>
</tr>
<tr>
<td>15:45</td>
<td>Advanced therapies: where are we now with CART and BITEs</td>
<td>Maaike De Ruijter (NL)</td>
</tr>
<tr>
<td>16:00</td>
<td>Big issues: Sex and sexuality after transplant</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
08:45 - 09:40  Session 9: Preparing for CAR-T  
**Chairs: Maeve O’Reilly (UK) & Candice Hendricks (ZA)**  
08:45 - 09:05  Safety issues of gene therapy and gene editing  
Fabio Ciceri (IT)  
09:05 - 09:25  Principles of CAR T and TCR editing  
Matteo Doglio (IT)  
09:25 - 09:40  Discussion

09:40 - 11:00  Session 10: Early and late complications  
**Chairs: Raffaella Greco (IT) & Justin Du Toit (ZA)**  
09:40 - 10:00  Early complications post-CAR-T infusion  
Maeve O’Reilly (UK)  
10:00 - 10:10  Case Presentation Acute Myeloid Leukemia Development after  
Long-Lasting Immune Effector Cell-Associated Hematotoxicity  
Elisa Linnea Lindfors Rossi (SE)  
10:10 - 10:30  Late complications Hematotoxicity  
Marion Subklewe (DE)  
10:30 - 10:40  Case Presentation  Challenges in Chimeric Antigen Receptor-T cell  
product administration in a high tumor-burden elderly patient with  
mantle-cell lymphoma  
Umberto Pizzano (IT)  
10:40 - 11:00  Discussion

11:00 - 11:30  Coffee Break

11:30 - 13:00  Session 11: Indications for CAR-T in Adults  
**Chairs: Valentín Ortiz-Maldonado (SP) & Natacha Bolaños (ES)**  
11:30 - 11:50  CAR-T in ALL  
Nicolas Boissel (FR)  
11:50 - 12:10  CAR-T in PCD  
Nico Cagelmann (DE)  
12:10 - 12:30  HCT & CAR-T for lymphomas  
Anna Sureda (SP)  
12:30 - 12:40  Case Presentation: Double CART19/ALLO-HCT tandem as a management  
strategy for very advanced stage relapsed / refractory adult b-cell  
acute lymphoblastic leukemia  
Helena Brillembourg (ES)  
12:40 - 12:50  Case Presentation CAR-T cell therapy for refractory lymphoma and  
sle: a promising breakthrough  
Carolina Arevalo (ES)  
12:50 - 13:00  Discussion

13:00 - 13:15  Closing remarks & Poster award